Third, while exposure to SGLT2 inhibitors and DPP-4 inhibitors was excluded in the GLP-1 RA group, the potential effects of other antidiabetic medications could not be fully eliminated and may have influenced outcome assessment
For metabolic dysfunction where liver fat is driving risk, retatrutides mechanism may prove more relevant but that awaits outcome trials
Furthermore, most patients who start treatment with GLP-1RA for obesity discontinue treatment within 1 year because of side effects, high cost, or reaching a plateau in weight loss [106]
As a result, we eat less because we are thinking less about food, and we are satisfied with smaller portions even if we werent overeating
That is a conversation to have with your GP or a specialist haematologist, not a reason to add a private injection on top of an NHS schedule without telling either provider
Cannot redeclare control with same name "grid_1_section_price_style"